Catalog No.
DHD17201
Host species
Homo sapiens
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
2.87mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P16410
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
BMS-734016, MDX-010, MDX-CTLA-4, CAS: 477202-00-9
Note
For research use only. Not suitable for clinical or therapeutic use.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, PMID: 33485464
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer, PMID: 29355075
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, PMID: 30134131
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma, PMID: 30124333
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer, PMID: 30110194
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study, PMID: 31345627
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma, PMID: 30334646
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer, PMID: 29731394
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial, PMID: 32416781
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort, PMID: 31629915
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial, PMID: 32916128
Ipilimumab: an investigational immunotherapy for glioblastoma, PMID: 32945231
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials, PMID: 29370992
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis, PMID: 30789633
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1, PMID: 33485960
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial, PMID: 32852531
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial, PMID: 32853585
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer, PMID: 32238575
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma, PMID: 28981385
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609, PMID: 31880964
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials, PMID: 32580338
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma, PMID: 29975414
The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review, PMID: 31348136
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis, PMID: 33239030
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer, PMID: 27458307
Ipilimumab-induced hypophysitis, a single academic center experience, PMID: 31327112
Ipilimumab-Induced Secondary Hypophysitis, PMID: 29624100
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer, PMID: 32101673
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer, PMID: 32101672
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response, PMID: 32414761
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer, PMID: 31002006
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter, PMID: 32414760
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, PMID: 26787752
Ipilimumab for the treatment of metastatic prostate cancer, PMID: 29271259
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy, PMID: 33189597
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis, PMID: 28495807
Ipilimumab-Induced Sarcoidosis and Thyroiditis, PMID: 28207422
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis, PMID: 32620130
Ipilimumab induced digital vasculitis, PMID: 29433584
Pemphigus associated with ipilimumab therapy, PMID: 33410503
Ipilimumab-associated cholestatic hepatitis: a case report and literature review, PMID: 28489679
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma, PMID: 33188050
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. Reply, PMID: 32101674
Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma, PMID: 32416774
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA), PMID: 30871493
Immune Checkpoint Inhibitors-Induced Hepatitis, PMID: 30539511
ANCA-associated vasculitic neuropathy during treatment with ipilimumab, PMID: 31209477
[Alopecia areata under ipilimumab], PMID: 29653853
Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects, PMID: 29303446
Ipilimumab-induced renal granulomatous arteritis: a case report, PMID: 31604452
For research use only. Not for human or drug use.
